Cemiplimab, cutaneous squamous cell carcinoma, anti-PD1, comparative study
Melanoma, adjuvant treatment, Immunotherapy, BRAFi/MEKi, anti-PD-1, BRAF V600, overall survival, Recurrence-free survival